Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Background and Aims: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-modifying therapies (DMTs) on the efficacy to mount an appropriate immune respo...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publishing
2021-04-01
|
| Sarja: | Therapeutic Advances in Neurological Disorders |
| Linkit: | https://doi.org/10.1177/17562864211012835 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|